Fig. 1

Overall survival (OS) and recurrence-free survival (RFS) after initial treatment for colorectal liver metastasis. RFS rate was significantly better in patients who did not receive neoadjuvant chemotherapy (the NAC− group) than in those who received neoadjuvant chemotherapy (the NAC+ group) (P = 0.029). The OS rate was not different between the two cases